Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Tissue-specific Cell Therapy off the starting blocks with two promising Phase II projects

This article was originally published in Scrip

Executive Summary

Over the past two weeks, little-known UK-based stem cell therapy company Cell Therapy has reported impressive Phase II data with two of its products that target completely unrelated indications – advanced heart failure and severe tendon injury. CEO Ajan Reginald, previously Roche's global head of emerging technologies, spoke to Scrip about why the company chose to remain under the radar until recently, and of his ambitious plans to get a product onto the market in 2017.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC029143

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel